TAK-981 potentiated the activation and degranulation capacity of NK cells present in PBMCs from AML patients’, as measured by the increased expression at their surface of CD69 (Figure 3A) and CD107a (Figure 3B), respectively. This evidence concerns the gene CD69 and acute myeloid leukemia.